Home › NCT05718791
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients \>18 year old admitted for allo SCT PB for malignant disease.
About the study
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
What is being tested
- blood sample (diagnostic test)
Sponsor: Henry Ford Health System · Participants: 100 · Started: May 10, 2023
Contact the study team
- shatha farhan, MD · Phone: 3137133910
Official record on ClinicalTrials.gov — NCT05718791
Locations in the U.S.
| Michigan | Henry Ford Health System, Detroit |
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.